Abstract: Described are stable nanoparticle complexes comprising paclitaxel, albumin and rituximab. The nanoparticle complexes are suitable for the treatment of cancer.

Abstract: Described are nanoparticle complexes comprising paclitaxel, albumin and anti-CD52 antibody. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses CD52.

Abstract: The invention relates to methods for treating cancer (e.g., EGFR-expressing cancer) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and antibody-albumin nanoparticle complexes, said complexes comprising albumin, a cetuximab antibody and paclitaxel.

Abstract: Described are stable nanoparticle complexes comprising paclitaxel, albumin and ofatumumab. The nanoparticle complexes are suitable for the treatment of cancer.

Abstract: This invention relates to methods of making antibody-albumin nanoparticle complexes and pharmaceutical compositions thereof, comprising albumin, an antibody with binding specificity for a EGFR cetuximab), and paclitaxel, the methods comprising mixing in vitro an aqueous albumin-paclitaxel nanoparticle with an antibody with binding specificity for EGFR cetuximab) under conditions to form the nanoparticle complexes.

Abstract: Described are stable nanoparticle complexes comprising paclitaxel, albumin and alemtuzumab. The nanoparticle complexes are suitable for the treatment of cancer.

Abstract: This document provides methods and materials for treating cancer (e.g., skin cancer) with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies.

Abstract: Described are stable nanoparticle complexes of 100 nm to 900 nm comprising paclitaxel, albumin and an antibody. The nanoparticle complexes are suitable for the treatment of cancer.

Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Abstract: This invention relates to antibody-albumin nanoparticle complexes comprising albumin, trastuzumab, and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro such that the nanoparticle complex has antigen-binding specificity (e.g., HER2 binding specificity), for the purpose of providing cancer (e.g., HER2-related cancer) treatments in a subject in need thereof.

Abstract: This document provides materials related to treating cancer (e.g., skin cancer). For example, materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., albumin-bound paclitaxel/anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided).

Abstract: This document provides methods and materials related to treating myelomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD38 polypeptide antibody complexes) to treat myelomas are provided.

Abstract: Described herein are compositions of binding agents and carrier proteins, and at least one therapeutic agent, wherein the binding agents are capable of binding an antigen expressed on T-cells and methods of making and using the same, in particular, as a T-cell cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and at least one therapeutic agent, and methods of making and using the same, in particular, as a T-cell cancer therapeutic.

Abstract: Described herein are compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Still also described are methods for treating and/or increasing the therapeutic effectiveness of an immunotherapy of a patient suffering from a cancer which expresses PD-L1 or PD-L2 by administering to the patient a nanoparticle composition and a PD-1 immunotherapy.

Abstract: Described herein are nanoparticle compositions comprising binding agents, carrier proteins and an amount of paclitaxel derivative, and optionally a therapeutic agent. Also described herein are nanoparticle compositions comprising carrier proteins and an amount of paclitaxel, and optionally binding agents and/or a therapeutic agent, wherein the paclitaxel is present in an amount that is less than an amount that provides a therapeutic effect. Also disclosed herein are nanoparticles which contain (a) carrier protein, (b) a paclitaxel derivative, the paclitaxel derivative having reduced toxicity compared to paclitaxel, and optionally (c) a binding agent and/or (d) a therapeutic agent. Also described are methods of making and using the same, in particular, as a cancer therapeutic.

Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Abstract: Described are nanoparticle complexes comprising paclitaxel, albumin and anti-EGFR antibodies. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses EGFR.

Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Abstract: This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided.

Abstract: This invention relates to antibody-albumin nanoparticle complexes comprising albumin, bevacizumab, and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro such that the nanoparticle complex has antigen-binding specificity (e.g., VEGF binding specificity), for the purpose of providing cancer (e.g., VEGF-related cancer) treatments in a subject in need thereof.